Navigation Links
Spray on contraceptive clears Phase I trial

An Australian drug delivery company called Acrux specializes in administering medicines// through the skin. It has recently reported positive results for its Phase I clinical results of a contraceptive for women in the form of a spray.

The novel contraceptive spray called Nestorone MDTS is being developed in collaboration with a US-based research group 'The Population Council'. Interestingly the Phase I pharmacokinetic study showed that once-a-day dosing of the contraceptive spray Nestorone MDTS provided sustained delivery of the contraceptive agent.

Nestorone is a fourth-generation progestin is well tolerated, with no serious adverse events. A once a day application delivers consistent amounts through the skin to the blood stream. The contraceptive skin spray has the potential advantages of not having to be taken at exactly the same time each day and being suitable for breast-feeding mothers, according to Acrux, which also said the system has reduced skin irritation compared to patches.

The transdermal delivery system for drugs is a big market worth over $3 billion a year in the US alone and is growing at a rapid pace.

The transdermal delivery of drugs has some distinct advantages over oral or intravenous dosing of drugs. It avoids issues such as gastric irritability due to changes in pH that occur with oral dosing and variable transit times in the gut resulting in rapid fluctuations in plasma concentrations.
'"/>




Page: 1

Related medicine news :

1. Nasal Spray Could Take Drugs Direct to Brain.
2. Nasal Spray Could Take Drugs Directly to Brain
3. Nasal Spray Beats Antihistamine
4. Relief For British MS Patients: Cannabis-Based Oral Spray
5. Beware Of Bogus Claims by HGH Spray Internet Marketers
6. Spray-on skin: Effective in Relieving Stress of Child Burn Victims
7. Cluster Headaches Can Be Treated By Nasal Spray
8. Quick –fix Solution: Spray-on a Condom
9. Much Ado About Herbicide Sprays?
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. TEMPE Spray Delays Ejaculation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: